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Recent progress in the discovery of macrocyclic compounds as
potential anti-infective therapeutics
Abstract
Novel therapeutic strategies are urgently needed for the treatment of serious diseases caused by viral,
bacterial and parasitic infections, because currently used drugs are facing the problem of rapidly
emerging resistance. There is also an urgent need for agents that act on novel pathogen-specific targets,
in order to expand the repertoire of possible therapies. The high throughput screening of diverse small
molecule compound libraries has provided only a limited number of new lead series, and the number of
compounds acting on novel targets is even smaller. Natural product screening has traditionally been
very successful in the anti-infective area. Several successful drugs on the market as well as other
compounds in clinical development are derived from natural products. Amongst these, many are
macrocyclic compounds in the 1-2 kDa size range. This review will describe recent advances and novel
drug discovery approaches in the anti-infective area, focusing on synthetic and natural macrocyclic
compounds for which in vivo proof of concept has been established. The review will also highlight the
Protein Epitope Mimetics (PEM) technology as a novel tool in the drug discovery process. Here the
structures of naturally occurring antimicrobial and antiviral peptides and proteins are used as starting
points to generate novel macrocyclic mimetics, which can be produced and optimized efficiently by
combinatorial synthetic methods. Several recent examples highlight the great potential of the PEM
approach in the discovery of new anti-infective agents.
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Abstract: 
Novel therapeutic strategies are urgently needed for the treatment of serious 
diseases caused by viral, bacterial and parasitic infections, because currently used 
drugs are facing the problem of rapidly emerging resistance. There is also an urgent 
need for agents that act on novel pathogen-specific targets, in order to expand the 
repertoire of possible therapies. The high throughput screening of diverse small 
molecule compound libraries has provided only a limited number of new lead series, 
and the number of compounds acting on novel targets is even smaller. Natural 
product screening has traditionally been very successful in the anti-infective area. 
Several successful drugs on the market as well as other compounds in clinical 
development are derived from natural products. Amongst these, many are 
macrocyclic compounds in the 1-2 kDa size range. This review will describe recent 
advances and novel drug discovery approaches in the anti-infective area, focusing on 
synthetic and natural macrocyclic compounds for which in vivo proof of concept has 
been established. The review will also highlight the Protein Epitope Mimetics (PEM) 
technology as a novel tool in the drug discovery process. Here the structures of 
naturally occurring antimicrobial and antiviral peptides and proteins are used as 
starting points to generate novel macrocyclic mimetics, which can be produced and 
optimized efficiently by combinatorial synthetic methods. Several recent examples 
highlight the great potential of the PEM approach in the discovery of new anti-
infective agents. 
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1. Introduction 
Today, infectious diseases are the second major cause of death worldwide and the 
third leading cause of mortality in developed countries.[1] Due to the ability of 
bacteria, fungi, viruses and other pathogens to rapidly generate resistance towards 
established anti-infective drugs, there is increasing pressure on the pharmaceutical 
industry to come up with new lead compounds. Despite tremendous advances in 
early drug discovery technologies (e.g. combinatorial chemistry, genomics, and high 
throughput screening (HTS)), it has proven difficult to identify new anti-infective 
drugs. Most new compounds entering clinical development are follow-on compounds 
based on well-established drug classes. Compounds acting on novel pathogen-
specific target mechanisms are scarse. Hence, there is an urgent need to discover 
new anti-infective drugs with novel modes of action.[2, 3] 
 Natural products have played a crucial role in the development of novel anti-
infective drugs.[3] Amongst natural products, macrocyclic compounds clearly stand 
out. They often display remarkable biological activities and many of them (or their 
derivatives) have been successfully developed into drugs.[4, 5] The chemical 
diversity of macrocyclic natural products is immense and provides an invaluable 
source of inspiration for innovative drug design. Macrocyclic natural products 
generally exhibit semi-rigid backbone conformations, which place appended 
substituents in well-defined positions in space. Certain ring sizes are preferred. 
Sixteen membered rings, for example, are found frequently in oxygen-containing 
macrocycles, such as many polyketides.[4, 6] In cyclopeptides, ring sizes of 3n (n 
being the number of amino acids in the cycle) are observed most frequently (for n= 7, 
8, 11).[4] It seems that semi-rigid scaffolds may possess some of the favorable 
binding properties of rigid molecules (entropy), and yet are still flexible enough to 
adapt their conformations during a binding event (induced fit). 
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 Here we review the status of macrocyclic natural products, semi-synthetic 
analogues and novel fully synthetic macrocylic products in anti-infective research and 
development. The main focus will be on compounds that are in clinical development 
and research compounds with proven in vivo efficacy. The compound classes include 
cyclic macrolactones (excluding the well known macrolide antibiotics[7]), cyclic 
macrolactams, cyclic depsipeptides, cyclic peptides and cyclic polyamines. Finally, 
we will highlight a novel approach in drug discovery: the Protein Epitope Mimetic 
(PEM) technology[8, 9] and two programs that have resulted in interesting novel 
compounds in the anti-infective area.[10, 11] 
 
2. Macrocyclic antibacterials 
2.1 Introduction 
Increasing resistance of bacteria to currently available antibiotic treatments is an 
emerging public health crisis.[12] Two million patients acquire infections in hospital 
settings (nosocomial infections) in the U.S. alone, and of these 90’000 die each 
year.[1-3] Furthermore, some strains of resistant bacteria are no longer confined to 
hospital and are now becoming prevalent in the community across the U.S. and other 
countries.[13] In early 2006, the Infectious Diseases Society of America (IDSA) 
released a “hit list” of the six top priority, most dangerous drug-resistant microbes.[14] 
Among the Gram-positive bacteria, the most problematic are methicillin-resistant 
Staphylococcus aureus (MRSA), Staphylococcus epidermidis, vancomycin-resistant 
Enterococcus faecium and Enterococcus faecalis. A growing unmet medical need is 
represented by Gram-negative bacteria such as Pseudomonas aeruginosa. 
Increasingly alarming is the fact that 60% of the nosocomial pneumonias are caused 
by Gram-negative bacteria including P. aeruginosa (17%), Enterobacter species 
(17%), Klebsiella species (7%), E. coli (6%), H. influenzae (6%), and Serratia 
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marcescens (5%),[2] since success in finding new antibiotic leads against these 
organisms has been especially scarse. The incidences of hospital-acquired 
pneumonia caused by P. aeruginosa have nearly doubled from 9.6% in 1975 to 
18.1% in 2003.[3] Nowadays, novel approaches are particularly needed to treat 
resistant strains of Pseudomonas aeruginosa, Klebsiella pneumoniae, 
Stenotrophomonas maltophilia and Acinetobacter baumannii. Extended spectrum 
beta-lactamase (ESBL)-producing Gram-negative bacteria have also compromised 
the utility of many front-line beta-lactam drugs.[13] The scarcity of suitable new 
compounds is causing a revival in the use of “old” antibiotics like colistin, despite 
concerns about well-known toxicology problems.[15] 
 
2.2. Thiopeptide antibiotics 
The thiopeptide family of natural product antibiotics consist of ~80 compounds, and 
many of them have been known for over 50 years.[16, 17] Thiostrepton possesses 
antibiotic activity against MRSA and vancomycin-resistant Enterococcus faecalis 
(VREF), as well as cytotoxic activity against a number of cancer cell-lines.[18]  Most 
of the thiopeptide antibiotics inhibit protein synthesis in bacteria by binding to a cleft 
located between helices 43 and 44 of the 23S-rRNA and the ribosomal protein L11, 
thus inhibiting binding  of the GTP-dependent translation factor to the ribosome.[19]  
Some inhibit directly the GTP-dependent elongation factors, e.g. GE2270A[20] 
(Figure 1). A crystal structure has been determined of GE2270A in a complex with 
elongation factor EF-Tu,[21] revealing the conformation of the bound antibiotic and 
the mode of interaction with its protein receptor (Figure-1). 
 
<  Figure-1 > 
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Despite its high potency against some Gram-positive bacteria, including MRSA, the 
extremely low solubility of GE2270A has hampered its development. Using an 
integrated combinatorial and medicinal chemistry program, researchers at Vicuron 
discovered analogues of GE2270A with more favorable physico-chemical 
properties.[22] The total syntheses of six members of the class have been reported, 
including those of thiostrepton,[23] promothiocin A, amythiamicin D,[24] 
GE2270A,[25] GE2270T,[26] and siomycin A. 
 
2.3. Lysobactin/Katanosin 
Lysobactin[3, 27] was first isolated by scientists at Squibb from the fermentation broth 
of Lysobacter sp. SC-14076 (ATCC 53042).[28, 29] Independently, scientists from 
Shionogi discovered Katanosin A and B from a soil bacterium related to the genus 
Cytophaga (producer strain PBJ-5356) (Figure 2).[30] Katanosin B turned out to be 
identical to lysobactin. Bacterial cell wall biosynthesis is the primary target of these 
antibiotics, however, the mechanism of action is different from that of 
vancomycin.[31-33] The lysobactins are cyclic depsipetides containing several non-
proteinogenic D and L amino acids. In particular, four β-hydroxylated amino acids 
seem to be responsible for the remarkable hydrolytic stability of the amide bonds. On 
the other hand, the lactone bond in lysobactin is prone to hydrolysis.[34] However, its 
stable and highly potent amide analogue has been prepared.[35] The total syntheses 
of lysobactins have recently been highlighted.[27] 
 
<  Figure-2 > 
 
The crystal structure of lysobactin is characterized by a constrained cyclic peptide 
backbone stabilized by multiple intramolecular hydrogen bonds.[31] The two N-
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terminal leucine moieties are also involved in tight hydrogen bond and van der Waals 
contacts with the backbone (Figure-2). Lysobactin and katanosin A are highly active 
against Gram-positive bacteria, with significant activity against methicillin-resistant 
MRSA as well as vancomycin-resistant enterococci (VRE). In these pathogens sub-
micromolar MIC values are obtained, clearly superior to that of vancomycin. The high 
in vivo efficacy was confirmed in a systemic murine S. aureus infection model (ED50 
1.8 µg/kg i.v., CFU 105).[3] 
 
2.4. Glycopeptide antibiotics: dalbavancin, oritavancin and telavancin 
Vancomycin, introduced in 1959, and teicoplanin, are the two glycopeptides 
antibiotics that have been in clinical use for many years.[3, 36-39] They are regarded 
as the antibiotics of last resort against resistant staphylococci and enterococci,[36] 
However, the emergence of resistant strains has spurred on the search for active 
analogues of both vancomycin and teicoplanin.  
 Glycopeptides are active against most Gram-positive bacteria and a few 
anaerobic organisms such as Clostridium difficile. Vancomycin is bactericidal (except 
against enterococci) and acts by complexing the D-alanyl-D-alanine portion of 
peptide precursors in peptidoglycan biosynthesis, thus inhibiting peptidoglycan 
transpeptidase and transglycosylase reactions. 
 Despite some tremendous achievements in the total synthesis of 
glycopeptides antibiotics[40, 41] new analogues are generally obtained by semi-
synthesis from precursors (vancomycin, teicoplanin) produced by fermentation. 
Among the numerous glycopeptide analogues that were synthesized and clinically 
evaluated, dalbavancin (Versicor-Pfizer),[42] oritavancin (Lilly-Targanta)[43] and 
telavancin (Theravance-Astellas)[44] (Figure 3) are the most advanced.[45-47] 
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<  Figure-3 > 
 
 Dalbavancin exhibits an unusually long half-life (6-10 days) owing to high 
protein binding and hence can be administered once weekly.[48] From their 
pharmacokinetic and pharmacodynamic properties, oritavancin and telavancin seem 
to be the most promising vancomycin successors. 
 
2.5. Daptomycin 
Daptomycin (LY146032; Figure 4) is derived from A21978C lipopeptide factor C1, 
one of the fermentation products of Streptomyces roseoporus.[49, 50] Daptomycin 
belongs to the lipopetide family of antibiotics and consists of a 31-membered cyclo-
depsipeptide core and a tripeptide side-chain, which is acylated with a lipophilic 
group at its N-terminus. It was approved in 2003 for complicated skin and skin 
structure infections (cSSSI) and in 2006 for the treatment of blood stream 
infections.[51] It is active against S. aureus, coagulase-negative staphylococci, 
enterococci and streptococci. Daptomycin is rapidly bactericidal (less than one hour) 
and acts by bacterial membrane depolarization and disruption, which results in 
inhibition of macromolecular synthesis. It has a high protein binding (91-96%) and its 
activity is Ca2+ dependent.[51] Variations of the daptomycin structure revealed that 
two of the four aspartic acid residues are essential for activity.[38, 52, 53] 
<  Figure-4 > 
 
2.6. Ramoplanin and AC 98-6446 
Ramoplanin A2 is one the structurally most complex lipodepsipeptide antibiotics and 
exhibits extraordinary antibacterial activity against Gram-positive bacteria,[54, 55]  in 
particular, against drug-resistant Enterococcus faecium and MRSA. The ramoplanins 
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are produced by Actinoplanes ATCC 33076 and consist of a 49-membered ring 
composed of 17 amino acids (Figure 5), in which 12 of them possess unusual side-
chains and seven possess a D-configuration.[56] The 3D structure of ramoplanin 
established by NMR is characterized by two antiparallel beta-strands formed by 
residues 2-7 and 10-14, respectively, which are connected by a reverse beta-turn 
with Thr-8 at position i+1 and Phe-9 at position i+2.[57] The U-shaped conformation 
appears to be stabilized by a hydrophobic cluster of aromatic side chains from 
residues 3, 9 and 17.  
 
<  Figure-5 > 
 
 Ramoplanins inhibit bacterial peptidoglycan biosynthesis by binding to lipid 
II.[58] As a result, bacteria produce a weakened cell wall, which is sensitive to lysis. 
Several clinical studies have shown the utility of ramoplanin A2 in suppressing 
enterococcal infections and oral treatment of Clostridium difficile-associated diarrhea 
in the gastrointestinal tract in the nares (ointment). The molecule has been fast-
tracked by the US FDA for these indications.[54] Related to the ramoplanins are 
enduracidin A and B. 
 A semisynthetic mannopeptomycin AC 98-6446 (Figure 6) has been shown to 
have potent in vitro activity against a large number of resistant and sensitive 
staphylococci, enterococci and streptococci.[59] 
 
<  Figure-6 > 
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2.7. WAP-8294A2 
WAP-8294A2 (Figure 7) is a 40-membered cyclic depsipeptide containing 12 amino 
acids (7 with (R)-configuration) and one β-hydroxy acid. It was isolated from a Gram-
negative Lysobacter sp. in Japan.[60-62] WAP-8294A2 shows strong in vitro activity 
against Gram-positive bacteria including methicillin-resistant S. aureus (MRSA; MIC: 
0.49µM) and vancomycin-resistant enterococci (VRE; MIC: 3.93 µM) and is also 
highly active in vivo. The activity is increased in the presence of human serum and is 
14 times higher than vancomycin in a similar setting. WAP-8294A2 seems to damage 
the bacterial cell membrane by binding to phospholipids. WAP-8294A2 is expected to 
be clinically useful as a parenteral (i.v.) anti-MRSA agent. 
 
<  Figure-7 > 
 
2.8. Streptogramins 
Streptogramin antibiotics (Figure 8) are produced as secondary metabolites by a 
number of Streptomyces species and occur as synergistic mixtures of Group A (or M; 
polyunsaturated macrolactones) and Group B (or S; cyclic hexadepsipeptides) 
compounds.[37, 63, 64] The streptogramin family of antibiotics includes the 
mikamycins, pristinamycins, ostreomycins and virginiamycins. The first streptogramin 
antibiotic, pristinamycin (Figure 8), produced in Streptomyces pristinaespiralis, was 
developed in France more than 35 years ago and has been primarily used for the 
treatment of respiratory and skin structure infections.[65] 
 
<  Figure-8 > 
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 Pristinamycin consists of a variable mixture of pristinamycin Ia (24-38%) and 
pristinamycin IIa (54-68%) and is hardly water-soluble. Quinopristin/dalfopristin 
(30/70; Figure 9) was developed as a water-soluble derivative of pristinamycin with a 
selective spectrum against Gram-positive organisms. The synergistic 
quinupristin/dalfopristin mixture became available in the United States in 1999 for the 
treatment of infections caused by vancomycin-resistant Enterococcus faecium and 
those caused by other Gram-positive pathogens for which the other available agents 
are ineffective or not tolerated. The target of quinupristin and dalfopristin is the 
bacterial ribosome.  
 
<  Figure-9 > 
 
Dalfopristin blocks an early step of protein synthesis (elongation) whereas 
quinupristin blocks a subsequent step by inhibiting peptide synthesis. The effect of 
both drugs is thus inhibition of protein synthesis. [37] Crystal structures of 
quinuprisitin and dalfopristin bound to bacterial 50S ribosomal subunits have been 
reported (Figure 9).[66, 67] 
 
2.9. Biphenomycins 
Biphenomycin A (WS-43708A) was reported by scientists from Fujisawa in 1985[3, 
68] and was found to be identical with LL-AF283a isolated from S. filipinensis at the 
Lederle Laboratories in 1967.[69] A major discrepancy was noted between the in vitro 
and in vivo activity of biphenomycin (Figure 10). Administered subcutaneously along 
with S. aureus (ED50= 1 mg/kg) the compound was five-times more effective than 
vancomycin in a mouse septicemia experiment.[70] In vitro, however, the compound 
was virtually ineffective up to 200 µg/ml.  
 12 
 
<  Figure-10 > 
 
The synthesis of biphenomycin B was described in 1991 and opened up the 
possibility of producing more potent analogues.[71] A close analogue of 
biphenomycin B (Figure 10) showed an improved spectrum of activity in vitro. In 
particular, C-terminal amide derivatives showed improved in vitro activity and 
excellent in vivo efficacy.[72] Bacterial protein biosynthesis seems to be the target of 
this novel class of antibacterials.[3] 
 
2.10. Tuberactinomycins and Capreomycins 
The tuberactinomycin and capreomycin antibiotics (Figure 11) are cyclic 
pentapeptide natural product antibiotics.[3] Viomycin (tuberactinomycin B), 
discovered in 1951,[73] was marketed by Ciba and Pfizer as a tuberculostatic agent 
in the 1960s. The capreomycins were isolated from Streptomyces capreolus.[74-76] 
 
<  Figure-11 > 
 
 The tuberactinomycins and capreomycins show good activity against 
Mycobacteria including multi-resistant strains, however, only very limited activity 
against other bacteria. Intense efforts have been made to generate synthetic 
modifications of these interesting antibiotics, with the aim of broadening the anti-
bacterial spectrum.[3] Finally, by using de novo synthesis, scientists from Pfizer 
obtained compounds with significantly enlarged antibacterial spectrum (Figure 
12).[77-79] 
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<  Figure-12 > 
 
2.11. Enopeptins 
The enopeptins and closely related A54556 A and B (Figure 13) are 16-membered 
cyclic depsipeptides. The latter were described by researchers from Eli Lilly[80] in 
1985 and enopeptins A and B were isolated in 1991 from a culture broth of 
Streptomyces sp. RK-1051 in Japan.[81] Enopeptins are active against Gram-
positive and some Gram-negative membrane defective bacterial mutants. A total 
synthesis was described in 1997.[82] Researchers at Bayer have revised the initial 
structure of A54556A,[83] and have determined the mechanism of action.[84] The 
conformation has also been studied by NMR in DMSO solution.[85] 
 
<  Figure-13 > 
 
 The Bayer researchers identified casein lytic protease (ClpP) as the molecular 
target of these interesting antibiotics. Bayer initiated an optimization program around 
A54556 A and B in order to enlarge their in vitro spectrum, improve their ADME 
properties,[86] and to achieve in vivo activity. Extensive optimization resulted in 
potent synthetic analogues. A selected example is shown in Figure 14, which 
exhibited the following MICs (µg/ml): S. aureus (0.5); S. pneumoniae (≤0.125); E. 
faecium (≤0.125); E. faecalis (≤0.125).[3] In this project, efficient de novo synthesis 
rather than a fermentative/semisynthetic approach has been used to systemically 
explore the potential of the natural-product lead structures. 
 
<  Figure-14 > 
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2.12. Antimicrobial macrocyclic peptides 
Antimicrobial and host-defense peptides are important components of the innate 
immune defenses of all organisms.[87, 88] Cationic antimicrobial peptides possess 
significant activities against Gram-negative and Gram-positive bacteria, fungi, 
enveloped viruses and parasites.[89] These peptides can be linear or cyclic, and 
show a variety of secondary structures, including β-sheet, α-helical, extended and β-
turn structures. The compounds generally exhibit an amphipathic structure with a 
hydrophobic and a hydrophilic (cationic) face. The antimicrobial peptides target in 
general the bacterial membrane, however, in many cases they also interact with 
mammalian cells leading to significant toxic side-effects when applied systemically. 
For this reason, the application of antimicrobial peptides in the clinic has so far been 
limited to topical use. Nevertheless, antimicrobial peptides have generated a lot of 
interest as starting points for the development of new antibiotics, also due to the 
considerably low incidence of resistance. Among the macrocyclic antimicrobial 
peptides gramicidin S, tyrocidine, polymyxin B, protegrin I and its synthetic analogue 
IB-367 (iseganan) are perhaps the best known.[87] 
 
Tyrocidine A  
Tyrocidine A (Figure 15) belongs to a large class of peptide antibiotics related to 
gramicidin S, both of which were isolated from Bacillus subtilis. These antibiotics all 
contain a cyclic decapeptide core. Tyrothricin, a close analogue of tyrocidine A, has 
been used for topical treatment of Gram-positive bacterial infections, and like 
gramicidin S, is essentially limited to topical applications due to nephrotoxicity[90]. 
The molecule adopts a β-type amphipathic structure, which is the cause for the 
membranolytic mechanism of action.[91] 
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<  Figure-15 > 
 
Tyrocidine A associates preferentially with the bacterial outer cell wall, which is 
predominantly negatively charged, as opposed to the neutral membranes more 
commonly found in eukaryotes.[92] Approaches to improve the biological activity and 
the therapeutic index (as defined by the ratio of MHC/MIC; MHC, minimal hemolytic 
concentration) have been described.[92-95] 
 
Polymyxins (Colistin) 
Polymyxins were isolated in 1947 from different strains of Bacillus polymyxa.[15, 96, 
97] Polymyxins are highly active against a broad panel of Gram-negative bacteria, 
including Pseudomonas aeruginosa and Acinetobacter baumannii. Early 
administration of these antibiotics is associated with several reports of adverse renal 
and neurological effects in a large number of patients.[98, 99] Thus, compounds in 
this class of antibiotics were gradually withdrawn from clinical practice and replaced 
by newer antibiotics with the same or a broader spectrum, but were retained for the 
potential treatment of cystic fibrosis (CF) patients in combination with tobramycin. 
The emergence of Gram-negative bacteria that are resistant to all classes of 
available antibiotics except polymyxins, especially Pseudomonas aeruginosa and 
Acinetobacter baumannii strains, have led recently to a renaissance in their clinical 
use.[15] In particular, the previously reported toxicity of polymyxins has been 
carefully re-evaluated in the context of new dosing regimens.[100] 
 
<  Figure-16 > 
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 The family of polymyxins consists of five compounds, polymyxin A, B, C, D, 
and E (colistin), whereby only B and E have been used clinically. Colistin may contain 
different amounts of polymyxin A and B (see Figure 16), and is commercialized in two 
forms. Colistin sulfate is used orally for bowel decontamination and topically as a 
powder for skin infections, and as colistimethate sodium, which is applied 
parenterally and by inhalation. The prodrug colistimethate sodium is less active than 
the parent drug colistin, however, it is also less toxic. Toxicity is generally associated 
with the highly cationic, amphiphilic and thus hemolytic nature of the polymyxins. 
Polymyxin B sulfate is used parenterally, topically (ophthalmic and otic instillation), 
intrathecally, and by inhalation.[15] Several attemps have been made over the past 
years to find polymyxin analogues with a more favorable therapeutic index. For 
instance, acylation of Dab-9 with arginine results in a compound with an increased 
therapeutic window in vivo (LD50/PD50=60).[101] 
 
Protegrin 1 and IB-367 
Protegrin-1 (PG-1) is a cysteine-rich, 18-residue β-hairpin peptide isolated from 
porcine leukocytes and shows antimicrobial activity against a broad range of 
microorganisms (Figure 17).[102] The MICs of PG-1 against representative Gram-
negative and Gram-positive bacteria ranged from 0.12-2 µg/ml. At these levels PG-1 
is rapidly bactericidal in vitro, reducing the number of CFUs of either methicillin-
resistant MRSA or Pseudomonas aeruginosa by more than three log units in less 
than 16 minutes. Immunocompetent mice inoculated intraperitonealy (i.p.) with P. 
aeruginosa or S. aureus exhibited 97-100% mortality in the vehicle control group 
compared with 0-27% mortality in animals that received a single i.p. injection of PG-1 
(0.5mg/kg).[102] IB-367, a close relative of PG-1, was developed as an oral rinse 
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solution for the potential prevention of ventilator-associated pneumonia but failed in 
Phase III clinical development due to efficacy and toxicity problems. 
 
<  Figure-17 > 
 
 The structure of protegrin I has been studied in solution and in membrane 
mimicking environments, where it adopts a ß-hairpin structure.[103-105] In a 
membrane environment the hairpin has also been detected as a dimer (PDB 
1ZY6).[106, 107] 
 
3. Macrocyclic antivirals 
3.1. Introduction 
High-throughput screening of small molecule libraries has been more successful in 
discovering good leads in the antiviral than in the antibacterial area.[108] However, 
so far these leads hit only a limited number of targets. Well established targets 
include those involved in viral replication, including RNA-dependent DNA polymerase 
or reverse transcriptase for HIV, RNA-dependent RNA polymerase or RNA replicase 
for HCV, and viral proteases (aspartyl proteases for HIV and serine proteases for 
HCV).[109] More recent targets include inhibition of viral entry. Binding of HIV to 
CD4+ cells requires successive non-specific interactions with cell surface heparan 
sulphates, followed by specific binding to the CD4 receptor and the CXCR4 and/or 
CCR5 co-receptor, before the cell fusion process can occur. The binding of HCV to 
the cell surface and its entry into cells may involve the low-density lipoprotein 
receptor (LDLR), glycosaminoglycans (GAG), scavenger receptor class B (SR-BI, 
also known as SCARB1), among other events. Furthermore, HIV integrase, inhibition 
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of HIV maturation, and HIV and HCV cyclophilin inhibition have emerged as viable 
targets in the anti-viral field. 
 Natural product screening has been a valuable source for novel antiviral lead 
compounds. Among the macrocyclic products that are in clinical development as anti-
HCV compounds are ciluprevir[110] and ITM-191,[111] which inhibit the HCV NS3 
viral protease. In addition, Debio-025,[112] an inhibitor of cyclophilin, is an analogue 
of cyclosporin A lacking the immunosuppressive activity, and has emerged as an 
attractive candidate for the treatment of HCV. In the area of HIV inhibitors, the cyclic 
polyamine AMD3100,[113] callipeltin A[114] and a series of novel PEM-based 
CXCR4 antagonists with potent anti-HIV activity have emerged.[10] Furthermore, 
detruxin B [115] with activity against HBV constitutes another promising macrocyclic 
lead structure. 
 
3.2. Macrocyclic lead compounds for treatment of HCV 
BILN 2061 and ITMN-191 
HCV infection afflicts an estimated 170 million people world-wide. End-stage liver 
disease and liver failure resulting from HCV infection are currently the major causes 
of liver transplantation in the US and Europe.[109, 116] HCV is a small, enveloped 
single-stranded RNA virus. Current therapy involves application of pegylated 
interferons in combination with the broad-spectrum nucleoside analogue ribavirin. 
 The fully synthetic, orally available macrolactams BILN 2061 (cilepruvir)[110, 
116, 117] and ITMN-191 (Figure 18),[111] which potently inhibit the HCV encoded 
NS3 protease, have recently emerged as potentially interesting new therapeutics for 
HCV (Figure 18). As the NS3 protease plays a critical role in the maturation of the 
viral polyprotein precursor, it was recognized early on as a potential target for 
antiviral development.[115] BILN 2061 and ITMN-191 are reversible inhibitors of the 
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serine protease NS3 of HCV. Capitalizing on knowledge from known N-terminal 
linear hexa- and tetrapeptide cleavage products, which are potent inhibitors of the 
protease, BILN 2061 was obtained after several rounds of optimization.[110, 117] In 
particular, vinyl-ACCA was found as a potent replacement of cysteine at the P1 
position, and macrocyclization improved the ADME properties significantly. 
 
<  Figure-18 > 
 
 Ciluprevir inhibits the HCV NS3 protease in both in vitro enzymatic (IC50= 3 
nM) and cell-based replicon assays (EC50= 1.2nM). The compound shows good oral 
bioavailability in rats (F=42%) with low plasma clearance. A 2-day, twice-daily 
administration of ciluprevir to patients infected with HCV genotype 1 resulted in an 
impressive reduction of HCV RNA plasma levels (~3 log reduction) and provided the 
proof-of-concept in man. In recent toxicological studies in animals receiving high 
doses of ciluprevir for 4 weeks, cardiac toxicity was observed. As a result, clinical 
trials were put on hold. Modifications of the carboxylate group, e.g. into sulfonimides 
such as in ITMN-191,[111, 116] led to macrocyclic compounds with improved toxicity 
profile.[116] 
 
Debio-025 
More than a decade ago, cyclophilin A (Cyp A) was recognized as a target for the 
anti-HIV activity of cyclosporin A and non-immunosuppressive analogues such as 
Debio-025 (Figure 19).[109, 112] Cyp A binds specifically to the HIV-1 gag 
protein[118] and was also reported as a functional regulator of the HCV NS5B RNA 
replicase.[119] Debio-25 has strong inhibitory activity on HCV replication without 
exhibiting the immunosuppressive effect of cyclosporin A.[120] 
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<  Figure-19 > 
 
3.3. Macrocyclic lead compounds for treatment of HIV 
AMD3100 and related cyclic polyamines 
Binding of HIV to CD4+ cells requires successive non-specific interactions with cell 
surface heparan sulfates, followed by specific binding to the CD4 receptor and the 
CXCR4 and/or CCR5 co-receptor, before the cell fusion process can occur.[109] 
Fusion inhibitors for M-tropic HIV viruses to CCR5 and T-tropic viruses to CXCR4 
have become a focus in the search for novel anti-HIV therapies.[121] Among the 
macrocyclic lead compounds that inhibit CXCR4, the family of bicyclams such as 
AMD3100 and AMD 3465 (Figure 20) have emerged as first leads.[122]  
 
<  Figure-20 > 
 
AMD3100 shows potent activity against several strains of HIV-1 in the 1-10 ng/ml 
range, but it has to be administered by subcutaneous injection. In an open label 
dose-escalating phase I/II trial in HIV patients, one patient with pure X4 virus 
exhibited a clear viral load reduction.[123] However, AMD3100 induced cardiac 
adverse effects and the clinical development for HIV was discontinued. As an 
alternative, AMD3100 is currently being developed for stem cell mobilization in 
combination therapy with G-CSF.[121] 
 
Callipeltin A 
The 22-membered cyclic depsipeptide callipeltin A (Figure 21) and its congeners 
isolated from the marine sponge Callipelta sp. from New Caledonia exhibit potent 
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antifungal and anti-HIV activities.[55, 114] More recently, callipeltins A-C were 
isolated from the marine sponge Latrunculia sp. from Venatu Islands.[124] The 
identification of the three unusual amino acids was achieved by synthesis.[125] The 
most relevant biological activity of callipeltins is their anti-HIV effect, clearly 
demonstrated in their action against CEM4 lymphocytic cells infected with HIV-1 (Lai 
strain; EC50= 6.6 nM).[114, 126] However, callipeltin A is also quite cytotoxic 
(EC50=0.19 µM). 
 
<  Figure-21 > 
 
 In addition to its anti-HIV activity, callipeltin A was found to have a positive 
ionotropic effect as a powerful inhibitor of the Na+/Ca2+ exchanger in guinea pig left 
atria.[127] Related to the callipeltins and the papuamides, neamphamide A a cyclic 
depsipeptide with potent anti-HIV activity was recently described.[128] Despite the 
relatively low therapeutic window, the callipeltins may serve as good starting points 
for the design of analogues with more favorable ADMET properties. 
 
4. Macrocyclic antifungals 
4.1. Introduction 
Fungi have emerged world-wide as an increasingly frequent cause of health-care 
associated infections.[129, 130] Whereas superficial fungal infections of the skin and 
nails can be treated successfully, the incidents of serious fungal infections are 
becoming an increasing concern.[131, 132] The key pathogens are Candida 
albicans, azole-resistent C. albicans, C. glabrata, C. krusei, C. parapsilosis, 
Aspergillus fumigatus and Cryptococcus neoformans.[130] Among the invasive 
fungal infections, Candida accounts for 70-90% and Aspergillus for 10-20% of the 
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cases. A rise in life-threatening systemic fungal infections has been reported in HIV 
patients who generally suffer from a compromised immune system. 
 Beside the standard treatment with the fungicidal (and toxic) polyene 
amphotericin B, and the fungistatic (but safer) azoles such as fluconazole and 
itraconazole, the family of echinocandins[133] has successfully entered the market. 
Both amphotericin B and the echinocandins are derived from macrocyclic natural 
products. A water-soluble macrocyclic polyene derivative SPK-843[134, 135] entered 
phase II clinical trials for systemic mycosis in November 2004 and its efficacy in 
candidiasis was superior to that of amphotericin B (see also next paragraph). 
 
4.2. Amphotericin B 
Synthetic and semi-synthetic polyene macrolactone antifungals bind primarily to 
ergosterol, resulting in alterations in membrane permeability and leading ultimately to 
cell death.[129] Used since 1950, amphotericin B (Figure 22) is considered to be the 
gold standard for therapy of numerous serious invasive fungal infections.[136, 137] 
Amphotericin B is fungicidal and exhibits a broad spectrum activity against serious 
invasive pathogens like candida, aspergillus and cryptococci.  
 
<  Figure-22 > 
 
 Amphotericin B is used clinically as a deoxycholate, lipid complex, colloidal 
dispersion, and as a liposomal formulation.[136] This formulation was efficacious in 
the treatment of invasive aspergillus [138] and its renal safety was proven in 106 
patients with cryptococcal infection.[139] A water-soluble macrocyclic polyene 
derivative SPK-843 entered phase II clinical trials for systemic mycosis in November 
2004, and its efficacy in candidiasis was superior to that of amphotericin B. 
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4.3. Echinocandins 
The echinocandins, first discovered in 1974 (Figure 23), are a growing family of cyclic 
lipopeptide antifungal natural products.[140] They are macrocyclic hexapeptides 
containing a labile hemiaminal moiety and fatty acid that is N-linked to the peptide 
core. Furthermore, they are composed of four β-hydroxylated non-natural amino 
acids, including 3-hydroxylated and 4-hydroxylated proline residues. The 
echinocandins have been synthetically modified after extraction from the fermentation 
broths of various fungi.[129] Caspofungin is derived from Glarea lozoyenisi, 
micafungin from Coleophoma empedri, and anidulafungin from Aspergillus nidulans. 
Recently, a semi-synthetic three step synthesis of caspofungin from pneumocandin 
Bo has been described.[141] Echinocandins act mechanistically at the level of cell 
wall β-1,3-glucan synthesis by inhibition of β-1,3-glucan synthase.[142] This inhibition 
results in osmotic lysis of the cell leading to fungicidal activity against Candida 
sp.[143, 144]  
 
<  Figure-23 > 
 
These agents show a broad-spectrum activity and resemble each other with respect 
to in vitro activity against Candida sp., with micafungin and anidulafungin showing 
generally lower MICs than caspofungin. 
 Caspofungin, micafungin, and anidulafungin are relatively safe and effective 
agents for the parenteral (i.v.) treatment of candida infections[133] and constitute 
valuable alternatives to azoles and polyenes for the treatment of serious invasive 
infections and have been approved by the US FDA. 
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4.4. Aureobasidin 
Aureobasidin A (basifungin, LY295337) belongs to a family of cyclic depsipeptide 
antifungals and is produced by Aureobasidium pullulans.[130, 145] Aureobasidin 
(Figure 24) contains two (S)-N-methyl valines, one (S)-N-methyl phenylalanine and a 
(S)-N-methyl-β-hydroxy valine, which is crucial for the antifungal activity. 
Modifications to amino acids at positions 6, 7 and 8, with the aim of improving the 
activity were attempted with limited success.[146]  
 
<  Figure-24 > 
 
Aureobasidin A is a substrate for ABC transporters,[147] such as the multi-drug 
resistance (MDR) subgroup, and competitively inhibits efflux of other substrates. 
Furthermore, it lacks activity on Aspergillus fumigatus. Nevertheless, aureobasidin A 
constitutes an interesting lead structure, which seems worthwhile to pursue. 
 
4.5. UK2A and UK3A 
A family of cyclic nine-membered dilactone natural products, including antimycin, 
UK2A and UK3A (Figure 25) have been isolated from Streptomyces sp. 517-02.[130, 
148-150] The three compounds show broad spectrum antifungal activity against C. 
albicans and Aspergillus spp. UK2A and UK3A are devoid of any antibacterial 
activity, as seen in antimycin, which is also quite cytotoxic.  
 
<  Figure-25 > 
 
In contrast to UK2A and UK3A, antimycin seems to rapidly stimulate intracellular 
production of reactive oxygen species.[151] The main mechanism of action for UK2A 
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and UK3A, however, is inhibition of mitochondrial electron transport and interference 
with in vitro respiration in both yeast and rat mitochondria. Hence, these compounds 
could be valuable lead structures for the design of drugs that target fungal 
respiration. 
 
4.6. Pseudomycins 
The pseudomycins (Figure 26)[55, 152, 153] are produced in large amounts by 
Pseudomonas syringae MSU 16H[154] and represent a new class of antifungal 
metabolites active against a broad range of plant pathogenic fungi, as well as 
Candida albicans, Cryptococcus neoformans, and Aspergillus fumigatus. The family 
comprises also the potent anthelmintic compounds PF1022 described in chapter 5. 
 
<  Figure-26 > 
 
 
5. Macrocyclic anthelmintics 
5.1. Emodepside (BAY 44-4400) and PF 1022A-D 
PF 1022A-D isolated from Mycella sterilia,[155] belongs to the family of 
pseudomycins (Figure 27; see also section 4) isolated from Pseudomonas 
syringae.[55] PF 1022A shows potent, broad spectrum anthelmintic activity with low 
toxicity.[156] After discovery of the avermectins and milbemycins, PF 1022A was 
seen as a prototype of a new class of anthelmintics. PF 1022A acts probably as a 
neurotoxin, however, the exact mechanism of action is still under investigation,.[157] 
 
<  Figure-27 > 
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 The high potential of PF 1022A as a new anthelmintic lead compound 
prompted the synthesis of a large number of analogues[158] with the aim of 
improving the biological activity and pharmacological properties. Emodepside (BAY 
44-4400), a semi-synthetic analogue of PF 1022A, is highly effective against a broad 
panel of intestinal and extraintestinal nematodes, and also against filarial 
parasites.[159] 
 
6. Protein Epitope Mimetics (PEM) technology: A novel approach in anti-
infective drug discovery 
6.1. Introduction 
The Protein Epitope Mimetics (PEM) approach to drug discovery is based upon the 
design of synthetic peptidomimetic molecules that mimic the functionally important 
epitopes in biologically relevant peptides and proteins, such as those based on β-
hairpin and α-helix secondary structure motifs. By transferring the epitope from a 
recombinant to a synthetic scaffold that can be produced efficiently by parallel 
combinatorial methods, the chemical, biological and drug-like properties of an initial 
hit can be optimized through iterative rounds of library synthesis and screening. 
 The β-hairpin is an especially interesting scaffold, which is used by many 
proteins for biomolecular recognition. β-Hairpins are amenable to mimetic design, for 
example, by transplanting a loop sequence from the protein or peptide of interest 
onto a synthetic template that can act to stabilize hairpin backbone conformations 
(Figure 28).[8, 10, 11] In the resulting macrocyclic peptidomimetics (or PEM 
molecules), additional stabilization of β-hairpin conformations may be achieved by 
introducing disulfide bonds between cysteine residues located at opposite, preferably 
non-hydrogen-bonded sites in each β-hairpin strand. The most commonly used 
template in the ß-hairpin PEM molecules studied so far is the dipeptide unit DPro-
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LPro, which adopts a very stable type-II' ß-turn, and so is ideal to nucleate ß-hairpin 
conformations. 
 
<  Figure-28 > 
 
 β-Hairpin template-bound PEM molecules can be rapidly and efficiently 
produced using a mixed solid- and solution-phase parallel synthesis process.[8] An 
enormous potential diversity can be generated in such synthetic molecules, simply by 
variations in the number and types of building blocks. The diversity achievable comes 
close to that seen within the large family of macrocyclic peptide-based natural 
products (vide supra). The production of PEM molecules can be carried out in a 
parallel combinatorial process that gives libraries typically containing several dozen 
PEM molecules. In iterative cycles of parallel PEM library synthesis and testing, initial 
hits can be optimized based on biological activity as well as ADMET properties. Due 
to their macrocyclic, conformationally constrained nature, these molecules can be 
endowed with excellent small molecule-like pharmacokinetic properties, which differ 
significantly from those of linear peptides. The 3D structures of PEM molecules both 
free in solution and in complexes with the target receptor were investigated by NMR 
and crystallography. The resulting 3D structure-activity relationships may then 
provide incisive SAR information that can feed back into the iterative library design 
and optimization process. The NMR structures of several PEM molecules, including 
two in complexes with their receptors, have been described earlier.[8, 11, 160-169] 
 
6.2. Antiinfective PEM molecules 
Nature has evolved remarkable mechanisms to protect animals from viral and 
microbiological attack, based on the innate and adaptive arms of the immune system. 
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Within the innate immune system, a first line of defense is provided by several 
families of peptides and proteins produced by immune cells, that possess 
antibacterial, antifungal and antiviral activities.[88, 170] Examples include the 
defensins, protegrins, cecropins, magainins, indolicidin and related cationic 
amphiphilic host-defense peptides. These peptides are gene-encoded, and are 
produced from precursor proteins through one or more proteolytic steps. Overall, 
their mechanisms of action are diverse and complex, ranging from a direct killing 
action by targeting bacterial cell membranes for disruption (e.g. the protegrins), to 
modulating the biological activity (gene expression, chemoattraction, differentiation, 
induction of cytokines and chemokines) of immune cells. These peptides, therefore, 
represent targets of outstanding interest for the PEM approach to drug design.  PEM 
molecules (Figure 28) based on anti-viral natural products like polyphemusin II,[171, 
172] and antimicrobial peptides such as protegrin I,[102] tachyplesin,[173] and RTD-
1,[174] represent an ideal starting point for the design of novel antibacterial and 
antiviral agents (Figure 29). 
 
<  Figure-29 > 
 
6.3. Antimicrobial PEM molecules 
Cationic amphiphilic antimicrobial peptides comprise a large family of compounds 
showing broad-spectrum antimicrobial activity against Gram-positive and Gram-
negative bacteria. The main mechanism of action seems to involve lysis of the 
bacterial cell membrane.[175] Indeed, the strong hemolytic activity of antimicrobial 
peptides on typical eukaryotic (e.g. red blood) cells, has so far limited their clinical 
use to topical applications. 
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 The first starting point for PEM design was the antimicrobial peptide protegrin I 
and its closely related synthetic analogue IB367 (chapter 2.12). Libraries of PEM 
molecules incorporating sequences related to protegrin I were synthesized and 
optimized, to afford compounds possessing potent broad spectrum antimicrobial 
activity.[11, 176] By iterative library screening it was possible to to obtain analogues 
such as 1 with considerably reduced hemolytic activity on red blood cells (Figure 30). 
A stable hairpin conformation for 1 was observed by NMR, but only in a micelle 
(membrane-like) environment.[11] SAR studies, involving the synthesis and testing of 
a large number of single site substituted analogues, showed that the antimicrobial 
activity was tolerant to a large number of the changes made.[176]  
 
<  Figure-30 > 
 
Efforts have been made to understand the observed antimicrobial and hemolytic 
structure-activity relationships in terms of a QSAR model.[177] The best model 
suggested that the antimicrobial potency correlates with the peptide charge and 
amphipathicity, while the hemolytic effects correlate with the lipophilicity of residues 
forming the non-polar face of the ß-hairpin. Related β-hairpin mimetics have also 
been made with a mixed peptide-peptoid backbone (4 and 5),[168] while others 
contain templates based on a xanthene[11] (2) or a biaryl derivative (3).[178] Many of 
these molecules retain potent broad spectrum antimicrobial activity, and are 
potentially interesting starting points for further optimization. 
 More recently, a new structure-activity trail has provided access to derivatives 
with a much higher potency and selectively against Pseudomonas aeruginosa. These 
new derivatives do not cause cell lysis, and only one enantiomer retains significant 
potency, suggesting a different mechanism of action (to be published). One of these 
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molecules, POL7001, exhibits potent in vitro activity against a broad panel (>125 
strains) of Pseudomonas strains (including multidrug-resistant clinical isolates from 
CF patients) with a MIC90= 0.2 µg/ml. In addition, POL7001 showed potent activity in 
an in vivo septicemia mouse model against P. aeruginosa PAO1 (EC50= 0.3 mg/kg) 
and was 10 times more potent than gentamycin tested in the same model. Hence, 
these PEM molecules may constitute a novel class of antibiotics. They show great 
promise in the fight against multidrug resistant P. aeruginosa, and one (POL7080) is 
currently in preclinical development. 
 
6.4. POL3026: A potent and specific CXCR4 inhibitor exhibiting strong anti-HIV 
activity 
The chemokine receptor CXCR4 and its ligand CXCL12 (SDF-1α) have also 
emerged recently as important therapeutic targets. CXCR4 inhibitors are of great 
interest in hematopoetic stem cell mobilization, cancer, inflammation and HIV. 
CXCR4 was first discovered as a co-receptor, with CD4, for the entry of T-tropic (X4) 
HIV-1 into T-lymphocytes.[179, 180] One of the first inhibitors of CXCR4 described 
was the natural peptide polyphemusin II,[171, 172] and a closely related synthetic 
analogue T22 ([Tyr5,12, Lys7]-polyphemusin II),[181] (Figure 29). T22 exhibits a well-
structured β-hairpin conformation by NMR,[182] and thus constituted a good starting 
point for PEM design. Several PEM libraries were synthesized and tested in iterative 
rounds of optimization. POL3026 (Figure 31) shows potent inhibition of CXCR4 
(IC50= 1.2nM, Ca-flux assay) and good pharmacokinetic properties.[10] The high 
activity of POL3026 was further confirmed in several anti-HIV tests,[183] including an 
in vitro cell fusion assay (FIGS), virus replication assays (deCIPhR), and acute CEM 
cell infection assays. 
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<  Figure-31 > 
 
7. Summary and outlook 
Macrocyclic natural products constitute the largest group of molecules among the 
compounds that are currently in preclinical and clinical stages in the antiinfective 
area. Due to their virtually unlimited diversity, natural products are also a rich source 
of inspiration for the development of novel lead compounds. Although many ring 
sizes are observed in macrocyclic natural products it is interesting to note that some 
ring sizes are over-represented.[4] It seems that in cyclic peptide and depsipeptide 
natural products, various hairpin-like and β-turn conformations are favored (vide 
supra). 
 We have also highlighted in this review the Protein Epitope Mimetics (PEM) 
technology, which constitutes a new approach in drug discovery. PEM molecules can 
mimic the β-hairpin and α-helical secondary structure elements often observed in 
protein-protein interactions. POL7080 and POL6326 were derived from the β-hairpin-
shaped natural peptides protegrin I and polyphemusin II. In rapid iterative cycles 
including design, synthesis, purification and biological profiling, optimized PEM 
molecules could be obtained with greatly improved ADMET properties compared to 
the starting natural products. The PEM approach thus efficiently generates fully 
synthetic compounds with drug-like properties, which display natural product-like 
structural complexity. While the anti-Pseudomonas compound POL7080 has moved 
into preclinical toxicological studies, POL6326 has successfully completed Phase I 
clinical studies for stem cell mobilization. 
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Figures and Legends 
 
Figure 1. Thiopeptide antibiotic GE2270A. Right, crystal structure of GE2270A bound 
to EF-Tu. The spheres indicate the hydrogen bond acceptors with the EF-Tu binding 
site (PDB 2C77). 
    
Figure 2. Structures of lysobactin and katanosin A. Right, the crystal structure of 
lysobactin (Cambridge Crystal Database CCDC_623590). 
 
Figure 3. Structures of dalbavancin, oritavancin and telavancin; and the crystal 
structure of vancomycin (PDB  1SHO).[184] 
 
Figure 4. Molecular formula and NMR structure of daptomycin (PDB 1XT7).[185] 
 
Figure 5. Molecular formula and NMR average solution structure (PDB 1DSR) of 
ramoplanin A2. 
 
Figure 6. Structure of AC 98-6446. 
 
Figure 7. Structure of WAP-8294A2. 
 
Figure 8. Structures of pristinamycin IA and IIA. 
 
Figure 9. Quinupristin and dalfopristin.  bottom left, crystal structure of quinupristin 
(PDB 1YJW) bound to the large ribosomal subunit.[66] The overall conformation is 
cup-shaped, with the phenyl and pyrrolidine rings stacked on each other at the 
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bottom of the cup. bottom right, crystal structure of dalfopristin also bound to a 
bacterial large ribosomal subunit (PDB 1sm1).[67] 
 
Figure 10. Structures of biphenomycins. 
 
Figure 11. Structures of tuberactinomycins and capreomycins. 
 
Figure 12. Structure of a synthetic analogue of the tuberactinomycins.[79, 186] 
 
Figure 13. Structures of ennopeptin A and B, A54556-A and A54556-B, and the 
average solution conformation of enopeptin A by NMR.[85] 
 
Figure 14. Structure of a synthetic analogue of the ennopeptins. 
 
Figure 15. Structure of tyrocidine A, and the average solution conformation 
determined by NMR.[91] 
 
Figure 16. Structures of polymyxin B1 and E, and the average solution conformation 
from NMR studies.[187] 
 
Figure 17. Structures of protegrin I and IB-367, and the average solution 
conformation of protegrin I in the membrane-bound dimer state (PDB 1ZY6). 
          
Figure 18. Structure of BILB 2061 and ITMN-191. 
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Figure 19. Structure of Debio-25. 
 
Figure 20. Structures of AMD3100 and AMD3465. 
 
Figure 21. Structure of callipeltin A. 
 
Figure 22. Structure of amphothericin B. 
 
Figure 23. Structures of echinocandins. 
 
Figure 24. Structure of aureobasidin A and conformation in the crystalline state 
(CCDC 143108). 
     
Figure 25. Structures of antimycin, UK2A and UK3A, and the conformation of 
antimycin A1 bound to mitochondrial cytochrome bc1 (PDB 1NTK).[188] 
  
Figure 26. Structure of pseudomycins A-C. 
 
Figure 27. Structure of emodepsipeptides. 
 
Figure 28. Structure of PEM molecules. ß-Hairpin PEMs typically comprise a peptide 
loop (e.g. 12 residues (X1 - X12) are shown below), linked to a ß-hairpin-stabilizing 
template (e.g. the D-Pro-L-Pro dipeptide shown below). The residues may be 
proteinogenic or non-proteinogenic amino acids, or even peptoid or related building 
blocks. 
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Figure 29. Structures of protegrin I, tachyplesin I and polyphemusin II. 
 
Figure 30. Antimicrobial PEMs based on the natural product protegrin I. Average 
solution NMR structures or mimetic 1 and 4 are also shown. 
 
Figure 31. Structure of POL3026. 
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